Trials / Completed
CompletedNCT01165203
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational Herpes Zoster (HZ) vaccine GSK1437173A in Human Immunodeficiency Virus (HIV) infected subjects, firstly enrolling subjects treated with antiretroviral therapy (ART) and with high CD4 T cell counts, and subsequently ART-treated subjects with low CD4 T cell counts, and ART-naïve subjects with high CD4 T cell counts. This Protocol Posting has been updated following Amendment 1 of the Protocol, August 2010. The impacted sections is exclusion criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes Zoster Vaccine GSK1437173A | intramuscular injection |
| BIOLOGICAL | Placebo | intramuscular injection |
Timeline
- Start date
- 2010-09-30
- Primary completion
- 2012-07-06
- Completion
- 2013-05-14
- First posted
- 2010-07-19
- Last updated
- 2018-04-30
- Results posted
- 2017-06-07
Locations
15 sites across 3 countries: United States, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT01165203. Inclusion in this directory is not an endorsement.